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ABSTRACT
Objectives To determine the age- specific clinical 
presentations and incidence of adverse outcomes among 
patients with COVID-19 in Jiangsu, China.
Design and setting Retrospective, multicentre cohort 
study performed at 24 hospitals in Jiangsu, China.
Participants 625 patients with COVID-19 enrolled 
between 10 January and 15 March 2020.
Results Of the 625 patients (median age, 46 years; 
329 (52.6%) men), 37 (5.9%) were children (18 years 
or younger), 261 (41.8%) young adults (19–44 years), 
248 (39.7%) middle- aged adults (45–64 years) and 79 
(12.6%) elderly adults (65 years or older). The incidence of 
hypertension, coronary heart disease, chronic obstructive 
pulmonary disease and diabetes comorbidities increased 
with age (trend test, p<0.0001, p=0.0003, p<0.0001 and 
p<0.0001, respectively). Fever, cough and shortness of 
breath occurred more commonly among older patients, 
especially the elderly, compared with children (χ2 test, 
p=0.0008, 0.0146 and 0.0282, respectively). The quadrant 
score and pulmonary opacity score increased with age 
(trend test, both p<0.0001). Older patients had many 
significantly different laboratory parameters from younger 
patients. Elderly patients had the highest proportion of 
severe or critically- ill cases (33.0%, χ2 test p<0.0001), 
intensive care unit use (35.4%, χ2 test p<0.0001), 
respiratory failure (31.6%, χ2 test p<0.0001) and the 
longest hospital stay (median 21 days, Kruskal–Wallis test 
p<0.0001).
Conclusions Elderly (≥65 years) patients with COVID-19 
had the highest risk of severe or critical illness, intensive 
care use, respiratory failure and the longest hospital stay, 
which may be due partly to their having a higher incidence 
of comorbidities and poor immune responses to COVID-19.
INTRODUCTION
COVID-19 infection causes a wide spectrum 
of disease, which may lead to respiratory 
failure and organ failure, leading to death. 
Most of the available studies prior to the 
COVID-19 pandemic found that people of all 
ages are susceptible to SARS- CoV-2 infection 
but noted higher positivity rates in real- time 
reverse transcriptase- PCR (RT- PCR) assays 
and hospitalisation burden in older people.1–3 
Similar to SARS, deaths and adverse clin-
ical outcomes have been found to be more 
common in the elderly with known comorbid-
ities for patients with COVID-19.4–6 Evidence 
suggests that asymptomatic carriers were 
more common among middle- aged people in 
close contact with infected family members.7 
One study found that elderly patients with 
COVID-19 had some different clinical features 
compared with younger patients.8 Because 
age is a host factor that leads to a higher risk 
of severe COVID-19 and worse prognosis, it 
is important to better understand age- related 
susceptibility and pathology. However, 
published data on age differences in clinical 
features and clinical outcomes associated with 
COVID-19 remain scarce. This study aimed to 
investigate differences in clinical character-
istics, disease severity and clinical outcome 
burden in different age groups of patients 
with COVID-19.
METHODS
Study design and participants
This retrospective cohort study included all 
patients who met the study’s inclusion and 
Strengths and limitations of this study
 ► This cohort consists of almost all COVID-19 pa-
tients in Jiangsu province, with a population of over 
80 million. Findings are, therefore, representative 
of the hospitalised patient population in the whole 
province. They are inclusive across the range of dis-
ease severity, so are subject to less selection bias.
 ► The study includes imported and local cases with 
different types of exposure.
 ► This is an observational exploratory study and our 
results may thus be subject to possible confounding 
factors and false- positive error.
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exclusion criteria. The inclusion criterion was up to 15 
March 2020, all patients diagnosed with COVID-19 in 
Jiangsu province according to the ‘Diagnosis and Treat-
ment Protocol for Novel Coronavirus Pneumonia (Trial 
Version 7)’ released by the National Health Commis-
sion and National Administration of Traditional Chinese 
Medicine of China.9 The only exclusion criterion was any 
patient with no available medical records. A standard 
criterion was set for discharge: a patient’s body tempera-
ture must be normal for more than 3 days, symptoms 
were resolved (if there were symptoms) and RT- PCR 
assays (throat swab samples, with at least 1 day sampling 
interval) showed two consecutive negative results.
Data collection and definition of variables
Epidemiological, clinical, laboratory and radiologic 
parameters on admission; disease severity (asymptom-
atic, mild, moderate, severe and critically ill) and clinical 
outcomes data were extracted from medical records. A 
clustered onset was defined as the occurrence of two or 
more confirmed COVID-19 cases in the same cluster/
group within 14 days, such as family, community, hospital, 
working place or public place. A clustered onset could 
occur from interpersonal transmission via close contact 
with, or joint exposure to, a confirmed COVID-19 case. 
Other cases not meeting the conditions of a clustered 
onset were classified as ‘single onset’. Disease severity was 
assessed at days 1, 2, 3, 4, 5, 6, 7 and 14 after admission, 
except for those who were discharged, and the highest 
degree of disease severity during the 14- day follow- up 
was selected for analysis. Data on mortality and other 
clinical outcomes were available until 15 March 2020. 
Asymptomatic infection was defined as the absence of 
clinical symptoms but with a positive nucleic acid test 
result. Mild disease was defined as having mild clinical 
symptoms and the absence of imaging manifestations of 
pneumonia in CT scans. Moderate disease was defined as 
the presence of fever, respiratory tract symptoms or other 
symptoms, and imaging manifestations of pneumonia. 
Severe disease was defined as the presence of at least one 
of the following conditions: respiratory distress, respira-
tory rate ≥30 breaths/min; oxygen saturation in resting 
state (SpO2) ≤93%; or arterial partial pressure of oxygen 
(PaO2)/fraction of inspired oxygen ≤300 mm Hg (1 mm 
Hg=0.133 kPa). Critically ill was defined as having respi-
ratory failure requiring mechanical ventilation, shock 
or combined organ failure requiring intensive care unit 
(ICU) monitoring and treatment. We categorised the 
population into four age groups: children (18 years or 
younger), young adults (19–44 years), middle- aged adults 
(45–64 years) and elderly adults (65 years or older).
All of the patients in Jiangsu had a high- resolution CT 
thorax examination to identify lung lesions. CT images 
were assessed visually by two radiologists who had more 
than 5 years of working experience in chest imaging. The 
radiologists were blinded to the patients’ characteristics. 
Quadrant scores were the sum of the number of quad-
rants containing pulmonary opacities extending from 
the proximal to the distal end of the chest, with a score 
ranging from 0 to 4. For pulmonary opacity, bilateral 
lungs were scored manually and assigned an estimated 
percentage of pulmonary opacity relative to the whole 
lung, rounded to the nearest 5%.
Statistical analysis
Normally distributed variables were summarised using 
mean (SD) by group and compared using analysis 
of variance tests, while skewed distributed variables 
were summarised using median (IQR) by group and 
compared using Kruskal- Wallis tests. Categorical variables 
were summarised using frequency and percentage and 
compared using χ2/Fisher exact test. To assess the linear 
trend effect of age on demographic and clinical vari-
ables, generalised linear models were employed with age 
(in years) as the only predictor. Normal distribution and 
identity link function were used for continuous variables, 
whereas binomial distribution and logit link function 
were used for binary variables. Analyses were performed 
using SAS V.9.4 (SAS Institute) and a two- sided p<0.05 
was considered statistically significant.
Patient and public involvement
Patients and the public were not involved in the design, 
conduct, reporting, or dissemination plans of this 
research.
RESULTS
Of the 721 suspected cases with possible COVID-19 during 
the study period, 631 patients were found to be RT- PCR 
positive for COVID-19. Only 625 patients were included 
in the study with complete data (figure 1). The median 
age was 46 years (IQR, 32–57; range, 0.75–96 years) and 
329 (52.6%) were men (table 1). Thirty- seven (5.9%) 
were children, 261 (41.8%) young adults of 19–44 years, 
248 (39.7%) middle- aged of 45–64 years and 79 (12.6%) 
elderly of 65 years or older.
There was no significant difference in the propor-
tion of men and women in each age group (table 1). 
The disease onset was clustered among a significantly 
higher proportion of young patients aged 18 years and 
below compared with older patients (aged 18 years and 
younger, young adult, middle- aged and elderly patients: 
78.4%, 43.3%, 52.8% and 53.2%, respectively, p=0.0005). 
The comorbidities incidence of hypertension, coronary 
heart disease, chronic obstructive pulmonary disease 
and diabetes increased with age (trend test, p<0.0001, 
p=0.0003, p<0.0001 and p<0.0001, respectively). Fever, 
cough and shortness of breath occurred significantly 
more commonly among young adult, middle- aged and 
elderly patients compared with children (67.8%, 68.5%, 
65.8% vs 35.1%, p=0.0008; 57.9%, 56%, 54.4% vs 29.7%, 
p=0.0146; 1.9%, 3.2%, 8.9% vs 0%, p=0.0282, respec-
tively). The frequencies of these symptoms were similar 
among different age groups of adults except for shortness 
of breath which was dramatically more common (8.9%) 
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in elderly adult patients aged 65 years or older. Compared 
with children and young adult patients, the incidence of 
smoking and drinking alcohol was significantly (twice the 
rate) higher among middle- aged and elderly patients. 
Three vital sign parameters on admission: systolic blood 
pressure (SBP) (mm Hg), diastolic blood pressure 
(DBP) (mm Hg) and SpO2 (%), changed linearly with 
age (trend tests, all p<0.0001). The quadrant score and 
pulmonary opacity score increased with age (trend tests, 
both p<0.0001).
Significant differences were observed in some labora-
tory test results (table 2). Older patients tended to have 
lower PaO2 (mm Hg) and partial pressure of carbon 
dioxide (mm Hg) in blood gas analysis. In blood tests, 
they had lower white blood cell count (109/L), lympho-
cyte count (109/L), haemoglobin level (g/L) and platelet 
count (109/L). In organ function tests, these patients had 
higher levels of alanine aminotransferase (U/L) and 
creatinine (µmol/L) and lower albumin levels (g/L). In 
inflammatory factor tests they had higher levels of C- re-
active protein (mg/L); and in coagulation function tests 
shorter activated partial thromboplastin time (s) and 
higher levels of fibrinogen (g/L) and D- dimer (mg/L).
The proportion of patients who received supportive 
treatment and antiviral and antibiotic therapy increased 
significantly with patients’ age, except for the very rare 
procedure of continuous renal replacement therapy and 
extracorporeal membrane oxygenation treatment and 
the very common use of interferon among different age 
groups (online supplemental table S1).
The proportion of patients with severe or critical illness 
was 33% among elderly patients, compared with 13% 
among middle- aged patients, 2.3% among young adult 
patients and 0% among children (p<0.0001) (table 3).
By the end of the study, none of the patients had died 
and all 625 patients had been discharged. The ICU rate 
(trend test, p<0.0001), respiratory failure rate (trend 
test, p<0.0001) and length of hospital stays (trend test, 
p<0.0001) increased with age (table 4). The proportion 
of patients requiring ICU care (p<0.0001) and developing 
respiratory failure (p<0.0001) among elderly patients was 
35.4% and 31.6%, respectively, compared with 14.5% 
and 12.5% among middle- aged patients, 2.3% and 1.9% 
among young adult patients and none among children, 
respectively. Elderly patients also had longer hospital stays 
(median (IQR), 21.0 (14.0–26.0) days) than all other age 
groups (15.0 (11.0–21.0) for children, 14.0 (11.0–19.0) 
for young adults and 17.0 (13.0–22.0) for middle- aged 
adults, p<0.0001).
DISCUSSION
To our knowledge, this is the largest cohort of 625 patients 
followed to date, to assess age differences in clinical 
features and clinical outcomes associated with COVID-
19. We observed that the majority (~80%) of COVID-19 
cases were among young adult patients of 19–44 years and 
middle- aged patients of 45–64 years, with the remainder 
of patients comprising children of 18 years or under 
(5.9%) and elderly patients of 65 years or over (12.6%). 
This is consistent with a previous study from Korea which 
reported 6.3% of cases with COVID-19 were children 
under 19 years old, a study which had tested the broadest 
and hence the most representative population during 
this study period.10
Our study showed that compared with adults, chil-
dren were more likely to get infected through cluster 
 
 
Figure 1: Study flow diagram 
 
721 suspected cases with possible COVID-19 were admitted in 24 hospitals in Jiangsu province 
from 10 January to 15 March 2020 
 
631 cases with confirmed COVID-19  
and quarantined 
90 cases excluded because real-time reverse transcriptase–polymerase chain 
reaction assays showed negative 
625 COVID-19 cases included in the analysis  
and quarantined 
6 cases excluded due to missing medical records  
and quarantined 
Figure 1 Study flow diagram.
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gatherings. A previous study reported that COVID-19 in 
children was mainly caused by family transmission.11
Our study in Jiangsu, found that all patients were 
discharged with no deaths. Elderly patients were more 
than twice as likely to have a severe or critical illness 
compared with middle- aged patients, while a smaller 
proportion of young adult patients had severe symp-
toms, and child patients exhibited none. The ICU use 
and respiratory failure rate, and length of hospital stay 
increased with age. Many case studies have shown that 
older patients are refractory (not yielding to treatment or 
not significantly improved after treatment) and likely to 
be at higher risk of more severe disease including acute 
respiratory distress syndrome (ARDS), respiratory failure 
and death,12–19 while younger patients are more likely to 
have a mild or moderate type of COVID-19.11 20 21 This is 
similar to SARS characteristics that, compared with adults 
and adolescents, the disease appears to be less severe in 
younger children.6
We found that initial symptoms including fever, cough 
and shortness of breath occurred more frequently among 
adults compared with child patients and especially short-
ness of breath was dramatically more common in elderly 
adult patients aged 65 years or older. This is consistent 
with the previous study showing that the older group 
(≥60 years) had a higher rate of shortness of breath than 
the younger group (<60 years).22 However, another study 
showed that only sore throat showed a significant differ-
ence between age groups but fever, cough, sputum and 
diarrhoea did not show differences, probably due to 
the small sample size.21 Another study which evaluated 
age difference only found four patients in total with 
symptoms of chest tightness or difficulty of breathing; 
however, the sample size (56 patients) was too small to 
draw any conclusions.8 Such symptoms may be the early 
signs of more severe illness and poorer outcomes in 
older patients. The frequency of these symptoms among 
adult patients in different age groups was similar except 
for shortness of breath, which was dramatically more 
common in elderly patients than younger adult groups 
in our study. This is different from the characteristics of 
influenza, where the initial clinical manifestations of frail 
elderly patients are usually subtle compared with young 
patients.23 24 In our study, the difference in vital signs of 
SBP and DBP on admission for different age groups were 
statistically significant (increasing with age) but may not 
be clinically significant.
Our study showed that the age differences in clin-
ical outcomes may also have partially resulted from the 
increased incidence of comorbidities with age, including 
hypertension, coronary heart disease, chronic obstructive 
pulmonary disease and diabetes. This may have increased 
susceptibility to the virus infection; such comorbidities are 
identified as risk factors of more severe disease including 
respiratory failure and death in patients with COVID-
19.13 17–19 25 Other explanations about why older people 
suffer poorer outcomes may be due to the higher preva-
lence of smoking and alcohol drinking in older patients 
with COVID-19 in Jiangsu. A history of smoking has been 
identified as a factor contributing to the progression of 
COVID-19 pneumonia.26
Our study demonstrated that the quadrant score and 
pulmonary opacity score increased with age, suggesting 
more severe abnormal imaging manifestation on admis-
sion among these older patients. This is consistent with 
the finding that the proportion of multiple lobe involve-
ment in older patients was higher than in younger cases.8 
Previous reports have also found some imaging differ-
ences by age groups; for example, primarily elderly 
patients were reported to have atypical imaging findings 
of consolidative opacities superimposed on ground- glass 
opacification,27 while paediatric patients showed more 
modest pulmonary involvement and less commonly 
reported consolidation complicated peripheral halo 
signs, compared with adults.28–30
Abnormal values in laboratory parameters in older 
patients may also be an early sign of, and a contribution 
to, severe illness and poor outcomes. This is consistent 
with previous studies showing the level of lymphocytes 
and albumin in the older cases was significantly lower 
and the level of C- reactive protein was higher than in the 
younger patients.8 21 Studies showed that albumin and 
C- reactive protein were associated with the progression of 
COVID-19 pneumonia,26 greater D- dimer on admission 
increased risk of in- hospital death,14 and organ and coag-
ulation dysfunction (eg, higher D- dimer) contributed to 
the development of ARDS and progression from ARDS 
to death.16
Table 3 Highest degree of disease severity of patients with COVID-19 during hospital stay by age group
Age group, n(%)
Highest degree of 
disease severity All (N=625)
Children 
(≤18 years) 
(N=37)
Young adulthood 
(19–44 years) 
(N=261)
Middle adulthood 
(45–64 years) 
(N=248)
Elderly 
(≥65 years) 
(N=79) P value
Asymptomatic 24 (3.8%) 8 (21.6%) 5 (1.9%) 7 (2.8%) 4 (5.1%) <0.0001
Mild 34 (5.4%) 11 (29.7%) 18 (6.9%) 4 (1.6%) 1 (1.3%)
Moderate 503 (80.5%) 18 (48.6%) 232 (88.9%) 205 (82.7%) 48 (60.8%)
Severe 30 (4.8%) 0 (0.0%) 4 (1.5%) 16 (6.5%) 10 (12.7%)
Critically ill 34 (5.4%) 0 (0.0%) 2 (0.8%) 16 (6.5%) 16 (20.3%)
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Our study indicated that lymphopenia (normal range: 
(0.3–3.0)×109/L) was shown in all age groups, but white 
blood cell and lymphocytes counts were lower in older 
patients, indicating that live SARS- COV-2 virus stimulated 
poorer responses in older patients. The mechanism in 
old patients with a severe COVID-19 illness may be that 
older patients have a diminished immune response to 
the novel SARS- COV-2 virus, which is a defence mecha-
nism against respiratory viruses and contributes to virus 
clearance. The thymic involution in older patients causes 
an age- related reduction of T cell repertoire diversity 
and defects in CD4+ and CD8+ T cell function and hence 
significantly reduces immune function (known as immu-
nosenescence).31 32 Immunosenescence makes many viral 
infections worse in older patients.33 But further research 
is necessary to investigate whether age differences in 
disease severity and outcomes of COVID-19 result from 
ageing of the immune system and reduced responsive-
ness. This is because some respiratory viruses could escape 
antiviral mechanisms and immune responses.34 For 
example, a study of H1N1pdm (respiratory viruses) on 
ferrets found no significant difference in viral clearance 
between young and adult subjects.35 However, studies 
found that the pulmonary pathology improved earlier in 
young ferrets, regulatory interleukin-10 (which is mainly 
produced by monocytes and lymphocytes) and interferon 
responses were more robust in young ferrets.35–37 Also, 
H1N1pdm infection triggered the formation of lung 
structures that resembled inducible bronchus- associated 
lymphoid tissues in young ferrets which contributes to 
pulmonary immune responses and were not seen in the 
adult ferrets with severe disease.35–37 Some other studies 
demonstrated aged ferrets infected with influenza viruses 
had reduced antibody production and delayed periph-
eral blood T- cell responses compared with adult coun-
terparts.31 32 38 Another study reported that, except for 
immunosenescence in older people, age- related increases 
in levels of phospholipase could also result in a delay of 
immune response and poor outcomes after SARS- CoV 
infection.33 Overall, research focused on innate immune- 
related mechanisms and viral clearance in patients with 
COVID-19 of different age groups may help determine 
the underlying mechanisms of disease severity.
Some other reasonable mechanisms of mild presenta-
tion in children include qualitatively different response 
to SARS- CoV-2, or different expression of ACE2 receptors 
required for SARS- CoV-2 infection, or different virus- 
to- virus interaction and competition from other viruses 
limiting SARS- CoV-2 growth.10
A larger proportion of older patients in this study 
received supportive treatment and antiviral and antibiotic 
therapies which was due in part to the increasing propor-
tion of severe or critical illness in older adults. Previous 
studies similarly showed that treatment was statistically 
different by age group.8 21
We believe that the findings from this study are gener-
alisable to populations in similar settings (eg, outside 
the initial pandemic centre) for two reasons: (1) we T
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included nearly all patients in Jiangsu province, China; 
(2) the study population consisted of cases confirmed by 
laboratory tests including those who were screened from 
suspected cases who had been to the pandemic centre 
(Wuhan), or had contact with people who had been to 
Wuhan or who had a confirmed diagnoses of COVID-19.
Our study has several limitations. First, the rela-
tively short follow- up time and a very small proportion 
of patients who remained in hospital after the 14- day 
follow- up period may have resulted in incomplete esti-
mates for disease severity. This would limit our interpre-
tation of age differences in the burden associated with 
COVID-19. However, this impact is minor and may not 
strongly affect the study results because we included 
analyses of clinical outcomes at the end of the study. 
Second, we were unable to perform multiple regression 
analysis to control for possible bias in the observed age 
impact on clinical features and outcomes. As a result, the 
observed age differences may still be subject to possible 
confounding factors. Third, this is an observational and 
exploratory analysis in which many statistical tests have 
been performed. As a result, there may be some false- 
positive results.
CONCLUSIONS
Older patients outside the pandemic centre of Wuhan, 
China, tended to have relatively more severe clinical 
infections and poorer clinical outcomes associated with 
COVID-19 compared with younger patients. Elderly 
patients aged 65 and older were at a much higher risk 
of developing severe or critical illness than other age 
groups. The ICU and respiratory failure rate, and length 
of hospital stay increased with age. Older patients had 
worse clinical outcomes, in part due to comorbidities in 
older people, and higher rates of smoking and drinking 
habits, and immune, organ and coagulation dysfunc-
tion on admission. In studying the pathogenesis and 
developing management strategies of COVID-19, age is 
confirmed as a critical factor in the severity of infection.
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